The Role of Hypoxia-Induced Factor-1 (Hif-1) in Cytoprotection Effect in Ischemic and Pharmacologic Postconditioning

Shcherbak, N. S.; Галагудза, М. М.; Шляхто, Е. В.

doi:10.15829/1560-4071-2014-11-70-75

Cited by 4 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Однако предполагаемое ограничение потока электронов в области третьего митохондриального ферментного комплекса под действием πQ-1104 [3] может лишь усугублять воздействие гипоксического фактора. Индуцированная толерантность к гипоксии путем ингибирования различных митохондриальных комплексов обсуждается в литературе [19]. Вместе с тем химическое прекондиционирование не может получить должного развития, т. к. его воздействие на организм чрезвычайно рискованно.…”

Section: результаты исследования и их обсуждениеunclassified

Potentiation of the hypoxic preconditioning effect by antihypoxants

Новиков

Егорович²,

Левченкова

et al. 2019

Rev Clin Pharm Drug Ther

View full text Add to dashboard Cite

The development of effective methods to increase the organism resistance to hypoxia is an important task of current medicine. One of such methods is preconditioning, as a result of which, a potent mobilization of the adaptive organism abilities occurs under a preconditioning factor action. Aim. To study the possibility of potentiating of the hypoxic preconditioning effect with help of antihypoxants. Methods. Evaluation of the effectiveness of combined preconditioning (antihypoxants + moderate hypobaric hypoxia) was performed on experimental models of acute hypoxia with hypercapnia, acute hypobaric hypoxia in mice, and bilateral occlusion of the common carotid arteries in rats. Investigated antihypoxants are amtizol, hypoxen, cobazole, metaprot, mexidol, mildronate, substances under the codes VM-606, pQ-4 and pQ-1104. Results. PreC with use of amtizol at dose 25 mg/kg, cobazole at dose 30 mg/kg, VM-606, pQ-4 and pQ-1104 at doses 50 mg/kg in combination with moderate hypoxia increased the lifespan of mice in acute hypoxia with hypercapniamodel and acute hypobaric hypoxia from 57 to 170%. Combined preconditioning with amtizol, cobazole and pQ-4 significantly increased the survival rate of rats in cerebral ischemia, amtizol and pQ-4 reduced neurological deficiency in the post ischemic period as well. Conclusion. Antitipoxants as amtizol, cobazole, VM-606, pQ-4, pQ-1104 potentiate the hypoxic preconditioning effect on acute hypoxia with hypercapnia, acute hypobaric hypoxia and occlusion of the common carotid arteries models, the most significant effect was noted for amtizol and pQ-4. Signal role in the adaptation induction to hypoxia and ischemia by combined preconditioning with use of antihypoxants hypoxia-inducible factor HIF-1α can play.

show abstract

Section: результаты исследования и их обсуждениеunclassified

Potentiation of the hypoxic preconditioning effect by antihypoxants

Новиков

Егорович²,

Левченкова

et al. 2019

Rev Clin Pharm Drug Ther

View full text Add to dashboard Cite

show abstract

“…Известно, что HIF-1 активируется в физиологически важных местах ре-гуляции кислородных путей, обеспечивая быстрые и адекватные ответы на гипоксический стресс [18]. Появляется всё больше сведений о том, что активация HIF является мощным защитным фактором при ИБС [19]. При этом считается, что стратегия выбора терапии с целью повышения экспресии HIF-1 может также способствовать ангиогенезу в ишемизированном миокарде.…”

Section: фармакологические свойства и механизм действия колхицинаunclassified

New Possibilities in the Treatment of Cardiovascular Disease Using Colchicine

Ватутин¹,

Смирнова²,

Целикова³

2016

Arhivʺ vnutr. med.

View full text Add to dashboard Cite

В представленном обзоре литературы отражены вопросы фармакологических свойств и механизма действия колхицина. Авторами предоставлены результаты ряда научных работ, посвященных изучению эффекта колхицина на течение сердечно-сосудистых заболеваний.

show abstract

Prognostic value of hypoxia-inducible factor-1 alpha gene polymorphism in patients with heart failure with preserved ejection fraction and obstructive sleep apnea

Yakovlev

Chernyshev

Sakhonchik

et al. 2022

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Aim. To study the associations of hypoxia-inducible factor-1 alpha (HIF-1α) gene polymorphism (rs11549465) with the clinical course of heart failure (HF) with reserved ejection fraction (HFpEF) in patients with obesity and moderate and severe obstructive sleep apnea (OSA).Material and methods. The study included 76 men with HFpEF and OSAS. Patients underwent a polysomnography, echocardiography, and a 6-minute walk test. In addition, apnea/hypopnea index was calculated, and the level of N-terminal pro-brain natriuretic peptide (NT-proBNP) was assessed. HIF1A gene polymorphisms (rs11549465) were analyzed using polymerase chain reaction. After 12-month follow-up, the clinical course of HF was assessed.Results. The T/T genotype of the HIF1A gene was associated with a high risk of HF progression (p=0,004), development of supraventricular premature beats (p=0,004) and atrial fibrillation (p=0,039). Carrying the T/T genotype was associated with severe OSA (p=0,006) and increased NT-proBNP (p=0,044), and also correlated with certain echocardiographic characteristics of myocardial remodeling.Conclusion. T/T genotype of the HIF1A gene is associated with OSA severity and increased NT-proBNP, as well as with the severity of left and right heart remodeling. The carriage of this genotype was associated with an unfavorable course of HF and an increased risk of atrial fibrillation in patients with HFpEF and OSA.

show abstract

The Role of Hypoxia-Induced Factor-1 (Hif-1) in Cytoprotection Effect in Ischemic and Pharmacologic Postconditioning

Cited by 4 publications

References 33 publications

Potentiation of the hypoxic preconditioning effect by antihypoxants

Potentiation of the hypoxic preconditioning effect by antihypoxants

New Possibilities in the Treatment of Cardiovascular Disease Using Colchicine

Prognostic value of hypoxia-inducible factor-1 alpha gene polymorphism in patients with heart failure with preserved ejection fraction and obstructive sleep apnea

Contact Info

Product

Resources

About